AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement
Generated by AI AgentAinvest Pre-Market Radar
Monday, Aug 18, 2025 4:26 am ET1min read
Aime SummaryOn August 18, 2025, Bioxcel Therapeutics' stock surged by 18.8% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Bioxcel Therapeutics has recently made headlines with the announcement of a phase III trial evaluating the safety of a 120-mcg dose of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia. This trial is part of the company's ongoing efforts to develop innovative treatments for mental health conditions, which has been a key driver of investor interest.
The upcoming release of SERENITY At-Home trial data this month is another significant event that has contributed to the positive sentiment surrounding
. The data is expected to provide further insights into the efficacy and safety of the company's treatments, potentially leading to regulatory approvals and expanded market opportunities.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Standard BioTools Inc. plunged 11.01% due to delayed clinical trial submissions and supply chain disruptions.
Dec.24 2025
United States Antimony Corporation shares surge 7.87% on operational advancements and sector tailwinds
Dec.24 2025
SEALSQ Shares Plunged 5.88% in Pre-Market Trading on Dec. 24 2025 as Heightened Investor Caution Ahead of Year-End Holiday Weighs
Dec.24 2025
ASST plunges 6.98% in pre-market as Bitcoin strategy volatility and market challenges weigh
Dec.24 2025
Poet Technologies (NASDAQ: POET) Falls 6.04% as Investor Caution Ahead of AI Infrastructure Execution Phase
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet